Navigation Links
Curemark CEO Presents at Epigenomics Conference
Date:8/24/2009

RYE, N.Y., Aug. 24 /PRNewswire/ -- Curemark Founder and CEO Dr. Joan Fallon delivered the Industry Keynote address at the Third International Epigenomics, Sequencing 2009 Conference at Harvard Medical School on July 14th.

Dr. Fallon's selection to address this cutting-edge conclave is particularly significant, since epigenetics is the study of heritable changes in gene function that occur without a change in the DNA sequence. Presenters at the session showcased many leading researchers, representing Harvard, Columbia and Duke Universities along with MIT and many others.

Dr. Fallon's message focused on Curemark's patented new science, which distinguishes a subset of children with autism. Labeled most recently by the geneticists as "the autisms", the multiple phenotypes which fall on the autism spectrum have yet to be fully delineated on a gene level. Curemark's science provides a route to identify a specific, diagnosable subset of children with autism.

"I'm honored to have been selected, among such distinguished leaders in both academia and industry, to speak at this conference," stated Fallon. "The opportunity to discuss Curemark's science in front of this esteemed group is so important to children with autism around the world as well as

to Curemark," she continued.

Curemark is presently conducting a FDA phase III clinical trial for autism.

About CUREMARK LLC

Curemark is a drug research and development company focused on the treatment of neurological and other diseases especially those with dysautonomic components by addressing certain key gastrointestinal/pancreatic secretory deficiencies. The company's initial products are based upon breakthrough observations by its founder, Dr. Joan Fallon, which revealed a lack of protein digestion in children with autism and ADHD. To learn more about our innovative science, visit www.curemark.com.

This news release contains forward-looking statements that involve risks and uncertainties that could cause our actual results and experiences to differ materially from anticipated results and expectations expressed in such forward-looking statement. These forward-looking statements include, without limitation, statements regarding the mechanism of action of CM-AT, its potential advantages, its potential for use in treating autism, as well as the timing, progress and anticipated results of the clinical development and regulatory processes concerning CM-AT. These statements are based on our current beliefs and expectations as to such future outcomes, and are subject to known and unknown risks and uncertainties that may cause actual future experience and results to differ materially from the statements made. Factors that might cause such a material difference include, among others, risks that the results of clinical trials will not support our claims or beliefs concerning the effectiveness of CM-AT, our ability to finance our development of CM-AT, regulatory risks, and our reliance on third party researchers and other collaborators. We assume no obligation to update these statements, except as required by law.


'/>"/>
SOURCE Curemark LLC
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Curemark Appoints Preeminent Pediatrics Gastroenterologist
2. Curemark Closes Series A Financing
3. Genaera Corporation Presents Interim Phase 1 Data for Obesity Compound Trodusquemine (MSI-1436) at IBC Conference
4. EntreMed Presents Data for Phase 2 Study of MKC-1 in Metastatic Breast Cancer
5. Pharmasset Presents R7128 Phase 1 Single Ascending Dose Study in Healthy Volunteers
6. Anadys Pharmaceuticals Presents Preclinical Results on ANA598, a Non-Nucleoside Inhibitor of the NS5B Polymerase, at the 14th International Symposium on Hepatitis C Virus and Related Viruses
7. CEL-SCI Presents Data for CEL-1000 as a Vaccine Adjuvant with Recombinant Hepatitis B Virus Protein
8. Ardea Biosciences, Inc. Presents Results of Phase 1 Studies of RDEA806, a Novel NNRTI for HIV, at 47th ICAAC
9. Targanta Presents First Data Demonstrating In Vitro Activity and In Vivo Efficacy of Prodrugs in Osteomyelitis Models
10. Wyeth Presents Phase 3 Fracture Data for Bazedoxifene, an Investigational Therapy for Osteoporosis
11. Aegerion Pharmaceuticals, Inc. Presents Final Results of Phase II Clinical Trials for AEGR-733 at Drugs Affecting Lipid Metabolism (DALM) 2007 Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2016)... 23, 2016 Global Paclitaxel Market ... profiles 12 companies and the Paclitaxel analysis in this ... the industry and its players. This is ... nature, details the current state of the industry while ... classifications, applications and industry chain structure. The Paclitaxel market ...
(Date:5/23/2016)... ALBANY, New York , May 23, 2016 /PRNewswire/ ... new market report titled, " Exocrine Pancreatic Insufficiency Market ... Forecast 2013 - 2023 ." According to the report, ... at a CAGR of 8.3% from 2015 to 2023 ... pancreatic insufficiency (EPI) is a condition characterized by the ...
(Date:5/23/2016)... Clarifying Vision - Prospects and Developments in ... What can be expected from the Ophthalmic ... the fastest rates? This visiongain report shows ... and prospects. ,Our 190-page report provides ... areas in the industry and the future market prospects. ...
Breaking Medicine Technology:
(Date:5/24/2016)... ... ... Sterling Global Products is launching a Kickstarter campaign focused on “PAW Patrol ... campaign kick-off video is located via this link https://youtu.be/WsO4qz2odco . The campaign will ... raise $1,000 per day for a total of $25,000. The funds will be used ...
(Date:5/24/2016)... , ... May 24, 2016 , ... ... of its services to provide one resource, from start to finish, for Life ... Life Safety Statement of Condition surveys requested by the Joint Commission, and fire ...
(Date:5/24/2016)... , ... May 24, 2016 , ... ... organization, is pleased to welcome new Partner Firm Austin & Co., Inc. ... approach to insurance, employee benefits, HR consulting, benefits technology, and beyond. As ...
(Date:5/24/2016)... ... May 24, 2016 , ... How to Write Error Free Procedures, ... http://www.fdanews.com/humanerrordrugdevice , Human error is known to be the major cause of quality ... ever be totally eliminated, many human performance problems can be prevented. , How to ...
(Date:5/24/2016)... ... (PRWEB) May 24, 2016 -- Grow Healthy ... Advisory Board. Joining the Grow Healthy Advisory Board team are ... embody the mission of our organization and bring talent, expertise and ... as we continue to expand our footprint as the leader in ...
Breaking Medicine News(10 mins):